title: Humoral immune response to Plasmodium falciparum vaccine candidate GMZ2 and its components in populations naturally exposed to seasonal malaria in Ethiopia.
abstract: BACKGROUND
  In Ethiopia, the general population is vulnerable to unpredictable epidemics of Plasmodium falciparum malaria. However, there is little information on the anti-malaria immune profile of the population in the endemic regions of the country.
  
  
  METHODS
  The study was designed to investigate the nature of humoral immune response to malaria in two ethnic groups in two endemic localities: Shewa Robit in north, and Boditi in south Ethiopia which are characterized by varying levels of malaria transmission and altitude. In a cross-sectional study, the study participants were diagnosed for malaria infection microscopically and by the rapid diagnostic test (RDT). Sera were tested by using enzyme-linked immunosorbent assay (ELISA) for total immunoglobulin (Ig) G against P. falciparum blood-stage vaccine candidate GMZ2 and its subunits (Glutamate-rich protein (GLURP-R0), merozoite surface protein 3 (MSP3); as well as IgG subclasses against GLURP-R0 and MSP3.
  
  
  RESULTS
  Whereas 23(8.6%) blood smear-positive cases for P. falciparum were detected in Boditi, all Shewa Robit study participants had no detectable P. falciparum infection. In both localities, total IgG prevalence and levels to GMZ2 were significantly higher than the response to the component domains indicating the strong recognition of GMZ2 by antibodies acquired through natural exposure. Total IgG and subclass prevalence and levels were higher in Shewa Robit than Boditi, suggesting difference in the intensity of malaria transmission in the two localities and/or genetic differences between the two populations in their response to the antigens. In both study sites, IgG subclass levels to GLURP-R0 were significantly higher than that to MSP3 for all corresponding subclasses in most individuals, indicating the higher relative antigenicity and probably protective potential of GLURP-R0 compared to MSP3. Against both GLURP-R0 and MSP3, the ratio of cytophilic to noncytophilic antibodies was >1 in the majority of the study participants, in both study sites, suggesting the induction of protective (cytophilic) antibodies against the two antigens. Analysis of age-related pattern in antibody levels against the antigens showed a positive association with increasing age.
  
  
  CONCLUSIONS
  P. falciparum GLURP-R0 and MSP3 separately as well as in a fused form in GMZ2 are readily recognized by the sera of the study populations. The significantly higher antibody prevalence and level detected against GMZ2 compared to either of its subunits separately, in naturally exposed populations, suggests the synergistic effect of GLURP-R0 and MSP3 and that GMZ2 could be a more relevant blood-stage malaria vaccine candidate than the individual components. Detection of high-level antibody responses in non-febrile, smear-negative individuals may possibly be an indication of a low-grade, asymptomatic sub-microscopic infection in the induction and maintenance of high-level malaria immunity.
authors: Microbial, Cellular and Molecular Biology Department, College of Natural Sciences, Addis Ababa University, P, O, Box 1176, Addis Ababa, Ethiopia. binmamo@yahoo.com
authors: Hassen
authors: H
authors: Mamo
authors: Meral
authors: M
authors: Esen
authors: Anthony
authors: A
authors: Ajua
authors: Michael
authors: M
authors: Theisen
authors: Benjamin
authors: B
authors: Mordmüller
authors: Beyene
authors: B
authors: Petros
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000913:Antibodies, Protozoan / Q000097:blood*; D000953:Antigens, Protozoan / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005002:Ethiopia; D005006:Ethnicity; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007223:Infant; D007231:Infant, Newborn; D017780:Malaria Vaccines / Q000276:immunology*; D016778:Malaria, Falciparum / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010963:Plasmodium falciparum / Q000276:immunology*; D055815:Young Adult
chemical_list: D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D007074:Immunoglobulin G; D017780:Malaria Vaccines
references: Vaccine. 2004 Mar 12;22(9-10):1188-98
references: 15003647
references: Infect Immun. 2008 Apr;76(4):1748-55
references: 18212081
references: PLoS One. 2009;4(3):e4708
references: 19262754
references: Parasite Immunol. 1999 Jul;21(7):335-40
references: 10417667
references: Eur J Immunol. 1988 Jan;18(1):123-31
references: 2450028
references: Adv Immunol. 1993;54:229-70
references: 8379463
references: Am J Trop Med Hyg. 1971 Mar;20(2):199-205
references: 4928591
references: Infect Immun. 1992 Apr;60(4):1473-81
references: 1548071
references: Clin Diagn Lab Immunol. 2005 Feb;12(2):242-8
references: 15699417
references: PLoS Med. 2007 Nov 13;4(11):e320
references: 18001147
references: Microbes Infect. 2002 Jan;4(1):31-5
references: 11825772
references: Clin Diagn Lab Immunol. 1995 Jan;2(1):30-4
references: 7719909
references: Infect Immun. 2000 Mar;68(3):1252-8
references: 10678934
references: Infect Immun. 2006 Jan;74(1):257-64
references: 16368979
references: Infect Immun. 2004 Jan;72(1):247-52
references: 14688102
references: Mol Biochem Parasitol. 1997 Dec 1;90(1):21-31
references: 9497029
references: Am J Trop Med Hyg. 2005 Dec;73(6):1096-103
references: 16354819
references: Clin Exp Immunol. 1986 Aug;65(2):427-33
references: 3791703
references: Vaccine. 2009 May 18;27(23):3090-8
references: 19428923
references: Vaccine. 2009 Nov 16;27(49):6862-8
references: 19755144
references: Vaccine. 2010 Sep 24;28(41):6698-703
references: 20696154
references: Cell. 2006 Feb 24;124(4):755-66
references: 16497586
references: Infect Immun. 2009 Mar;77(3):1165-74
references: 19139189
references: Infect Immun. 2008 May;76(5):2240-8
references: 18316390
references: N Engl J Med. 2011 Nov 17;365(20):1863-75
references: 22007715
references: Parasite Immunol. 2003 Jun;25(6):307-12
references: 14507328
references: J Immunol. 1995 Aug 1;155(3):1316-25
references: 7543519
references: Malar J. 2012 Feb 15;11:46
references: 22335967
references: Infect Immun. 2008 Feb;76(2):759-66
references: 18070896
references: J Exp Med. 1968 Mar 1;127(3):633-46
references: 4169968
references: PLoS Pathog. 2010 Feb 19;6(2):e1000770
references: 20174609
references: PLoS One. 2009 Oct 27;4(10):e7590
references: 19859562
references: BMC Infect Dis. 2010 Mar 08;10:55
references: 20205959